Signal
FDA schedules public hearing on national priority voucher program after four fast drug reviews
The FDA has announced a public hearing on June 12 to gather industry feedback on its National Priority Voucher program, launched last June. The program has enabled four ultra-rapid drug reviews so far, but its opaque nature has drawn scrutiny.
rss
clinical_trialsfdaapprovalsdrug_developmentregulation
Evidence locked
Today's free sample is only available for the edition's flagship signal.
Evidence preview
- Fierce Pharmafiercepharma.com
- FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed sharesBioPharma Dive
- The FDA has scheduled a public hearing for June 12 to hear input on the Commissioner’s National Priority Voucher prog...Fierce Biotech
- FDA seeks input into 'opaque' priority voucher schemepharmaphorum